Patients’ characteristics
| Patient . | Age . | Diagnosis . | Driver mutation . | Karyotype . | Molecular profile . | Treatments received . |
|---|---|---|---|---|---|---|
| MPN1 | 55 | PV | JAK2 | NA | JAK2 p.V617F. ASXL1 p.G646Wfs*12. EZH2 p.N688K. TP53 p.G245S. TP53 p.R175H. TP53 p.R248W. TP53 p.R248Q. TP53 p.Y234H. TP53 p.V172D. | Phlebotomy, interferon, ruxolitinib, idasanutlin |
| MPN2 | 76 | PMF | JAK2 | NA | JAK2 p.V617F. ASXL1 p.G819Efs*5. ASXL1 p.Q512*. DNMT3A p.R882H. TP53 p.Y163C | Ruxolitinib, EPO |
| MPN3 | 78 | PMF | JAK2 | 46.XY.del(13)(q1?2q1?4) [19]/46.XY[3] | JAK2 p.V617F. U2AF1 p.Q157P. TP53 p.C277Y. TP53 p.C242Y. | Hydroxyurea |
| MPN4 | 76 | ET | CALR | NA | CALR p.K385Nfs*47. TP53 p.H179R. TP53 p.R248W. | Hydroxyurea |
| MPN5 | 83 | PV | JAK2 | NA | JAK2 p.V617F. IDH1 p.R132H. DNMT3A p.V563M. TP53 p.C238Y. | Hydroxyurea |
| MPN6 | 82 | ET | JAK2 | NA | JAK2 p.V617F. TET2 p.S1059*. TET2 p.C1396Lfs*5 TET2 p.G1288D. TET2 p.R1216*. TP53 I255F | Hydroxyurea |
| MPN7 | 67 | PV | JAK2 | NA | JAK2 p.V617F. TET2 p.Q1654*. TP53 p.S241P | Pipobroman, interferon, hydroxyurea |
| MPN8 | 61 | Post-PV MF | JAK2 | NA | JAK2 p.V617F. TET2 p.I1873T. TET2 c.4537 + 3A > T. NFE2 p.T239Rfs*9. TP53 p.R175H | Phlebotomy, hydroxyurea, interferon |
| Patient . | Age . | Diagnosis . | Driver mutation . | Karyotype . | Molecular profile . | Treatments received . |
|---|---|---|---|---|---|---|
| MPN1 | 55 | PV | JAK2 | NA | JAK2 p.V617F. ASXL1 p.G646Wfs*12. EZH2 p.N688K. TP53 p.G245S. TP53 p.R175H. TP53 p.R248W. TP53 p.R248Q. TP53 p.Y234H. TP53 p.V172D. | Phlebotomy, interferon, ruxolitinib, idasanutlin |
| MPN2 | 76 | PMF | JAK2 | NA | JAK2 p.V617F. ASXL1 p.G819Efs*5. ASXL1 p.Q512*. DNMT3A p.R882H. TP53 p.Y163C | Ruxolitinib, EPO |
| MPN3 | 78 | PMF | JAK2 | 46.XY.del(13)(q1?2q1?4) [19]/46.XY[3] | JAK2 p.V617F. U2AF1 p.Q157P. TP53 p.C277Y. TP53 p.C242Y. | Hydroxyurea |
| MPN4 | 76 | ET | CALR | NA | CALR p.K385Nfs*47. TP53 p.H179R. TP53 p.R248W. | Hydroxyurea |
| MPN5 | 83 | PV | JAK2 | NA | JAK2 p.V617F. IDH1 p.R132H. DNMT3A p.V563M. TP53 p.C238Y. | Hydroxyurea |
| MPN6 | 82 | ET | JAK2 | NA | JAK2 p.V617F. TET2 p.S1059*. TET2 p.C1396Lfs*5 TET2 p.G1288D. TET2 p.R1216*. TP53 I255F | Hydroxyurea |
| MPN7 | 67 | PV | JAK2 | NA | JAK2 p.V617F. TET2 p.Q1654*. TP53 p.S241P | Pipobroman, interferon, hydroxyurea |
| MPN8 | 61 | Post-PV MF | JAK2 | NA | JAK2 p.V617F. TET2 p.I1873T. TET2 c.4537 + 3A > T. NFE2 p.T239Rfs*9. TP53 p.R175H | Phlebotomy, hydroxyurea, interferon |
EPO, erythropoietin; ET, essential thrombocythemia; MF, myelofibrosis; NA, not available; PMF, primary myelofibrosis; PV, polycythemia vera.